Cosentyx (secukinumab) is a medication used to treat certain autoimmune diseases such as psoriasis and psoriatic arthritis. However, the use of Cosentyx during pregnancy is not recommended due to potential risks to the developing fetus.

According to Drugs.com [3], Cosentyx has been assigned to pregnancy category B by the FDA, which means that animal studies have not shown any adverse effects on the fetus, but there are no well-controlled studies in pregnant women. Additionally, the drug is known to cross the placenta and may cause harm to the developing fetus.

A study published in the Journal of the European Academy of Dermatology and Venereology [2] analyzed the outcomes of pregnancies in women exposed to Cosentyx during pregnancy. The study found that out of the 16 pregnancies exposed to Cosentyx, one resulted in a miscarriage, one in a stillbirth, and one in a congenital anomaly. Although the sample size was small, the study suggests that there may be potential risks associated with the use of Cosentyx during pregnancy.

Furthermore, Drug Patent Watch [1] states that Cosentyx is not recommended for use during pregnancy unless the potential benefits outweigh the potential risks to the fetus. Pregnant women who are considering using Cosentyx should discuss the potential risks and benefits with their healthcare provider.

In conclusion, the use of Cosentyx during pregnancy is not recommended due to potential risks to the developing fetus. Pregnant women who are considering using Cosentyx should consult with their healthcare provider to weigh the potential benefits against the potential risks.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/
[3] https://www.drugs.com/pregnancy/secukinumab.html